Omnicell Business Summary

Omnicell, Inc. (OMCL) is a leading provider of medication management automation and business intelligence tools, operating through two primary segments: Product and Service. The company generates revenue via the sale of automated dispensing systems, such as the flagship Titan XT and XT Series, alongside a growing mix of recurring revenue from its OmniSphere cloud-native SaaS platform, technical services, and consumables. Its business model is increasingly pivoting toward a subscription-based "Autonomous Pharmacy" framework, targeting an Annual Recurring Revenue (ARR) exit range of $680 million to $700 million for fiscal year 2026. Omnicell competes directly with Becton, Dickinson and Company (BD), Swisslog Healthcare, and ScriptPro, maintaining a dominant market position as a specialized leader in end-to-end medication workflows for global health systems and retail pharmacies. The company was founded in 1992 by Randall Lipps, who continues to serve as Chairman, President, and CEO, leveraging a background in airline logistics at American Airlines to optimize healthcare supply chains. The leadership team was significantly bolstered in 2025 with the appointments of Chief Technology Officer Perry Genova, PhD—a med-tech veteran with 58 patents and former roles at GSK and EndoQuest Robotics—and Chief Financial Officer Baird Radford, who brings 30 years of finance experience from Intuitive Surgical and eBay. They are joined by COO Nnamdi Njoku, formerly of Zimmer Biomet and Medtronic. Omnicell’s board includes notable industry figures such as former Kimberly-Clark executive Joanne Bauer and former IBM executive Mary Garrett, supported by a high institutional ownership base exceeding 97%.